Multicentric Prospective Study to Assess the Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma
N/A
70 Years
N/A
70 Years
N/A
Open (Enrolling)
Both
Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma
Both
Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma
Trial Information
Multicentric Prospective Study to Assess the Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma
Sarcopenia status is assessed by CT scan imaging on the overall survival at 18 months in
patients older than 70 years with diffuse large B-cell lymphoma treated by R-CHOP.
Inclusion Criteria:
- Patients >= 70 years
- DLBCL, grade IIIB follicular lymphoma or histologically proven transformed low grade
lymphoma
- Whatever the IPI score and the performance status
- Treated by Rituximab-CHOP or Rituximab-mini-CHOP
- CT scan imaging performed one month or less before inclusion
- Signed informed consent
Exclusion Criteria:
- No initial CT scan imaging performed more than one month before inclusion
- Positivity for HCV, HBV and HIV
- Anthracycline contra-indication
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
progression free survival
Outcome Time Frame:
at 18 months
Safety Issue:
No
Principal Investigator
Fabrice JARDIN, MD;PhD
Investigator Role:
Study Director
Investigator Affiliation:
Centre Henri Becquerel
Authority:
France: Ministry of Health
Study ID:
CHB 11-02
NCT ID:
NCT01715961
Start Date:
January 2012
Completion Date:
June 2016
Related Keywords:
- Diffuse Large B Cell Lymphoma
- Grade IIIB Follicular Lymphoma
- 70 years old
- DLBCL
- Rituximab-CHOP
- Sarcopenia
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Sarcopenia
Name | Location |
|---|
